EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C21H25ClO6 |
| Net Charge | 0 |
| Average Mass | 408.878 |
| Monoisotopic Mass | 408.13397 |
| SMILES | CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1 |
| InChI | InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1 |
| InChIKey | JVHXJTBJCFBINQ-ADAARDCZSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Biological Roles: | anti-obesity agent Any substance which is used to reduce or control weight. insulin-sensitizing drug An agent which overcomes insulin resistance by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma). antiviral agent A substance that destroys or inhibits replication of viruses. sodium-glucose transport protein subtype 2 inhibitor Any inhibitor that interferes with the action of sodium-glucose transport protein subtype 2. |
| Applications: | antidepressant Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. cardiovascular drug A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume. antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. anti-arrhythmia drug A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. insulin-sensitizing drug An agent which overcomes insulin resistance by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma). hypoglycemic agent A drug which lowers the blood glucose level. antihypertensive agent Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. hepatoprotective agent Any compound that is able to prevent damage to the liver. geroprotector Any compound that supports healthy aging, slows the biological aging process, or extends lifespan. anti-inflammatory agent Any compound that has anti-inflammatory effects. renoprotective agent Any compound that is able to prevent damage to the kidneys. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| dapagliflozin (CHEBI:85078) has role anti-arrhythmia drug (CHEBI:38070) |
| dapagliflozin (CHEBI:85078) has role anti-inflammatory agent (CHEBI:67079) |
| dapagliflozin (CHEBI:85078) has role anti-obesity agent (CHEBI:74518) |
| dapagliflozin (CHEBI:85078) has role antidepressant (CHEBI:35469) |
| dapagliflozin (CHEBI:85078) has role antihypertensive agent (CHEBI:35674) |
| dapagliflozin (CHEBI:85078) has role antineoplastic agent (CHEBI:35610) |
| dapagliflozin (CHEBI:85078) has role antiviral agent (CHEBI:22587) |
| dapagliflozin (CHEBI:85078) has role cardiovascular drug (CHEBI:35554) |
| dapagliflozin (CHEBI:85078) has role geroprotector (CHEBI:176497) |
| dapagliflozin (CHEBI:85078) has role hepatoprotective agent (CHEBI:62868) |
| dapagliflozin (CHEBI:85078) has role hypoglycemic agent (CHEBI:35526) |
| dapagliflozin (CHEBI:85078) has role insulin-sensitizing drug (CHEBI:50864) |
| dapagliflozin (CHEBI:85078) has role renoprotective agent (CHEBI:231911) |
| dapagliflozin (CHEBI:85078) has role sodium-glucose transport protein subtype 2 inhibitor (CHEBI:73273) |
| dapagliflozin (CHEBI:85078) is a C-glycosyl compound (CHEBI:20857) |
| dapagliflozin (CHEBI:85078) is a aromatic ether (CHEBI:35618) |
| dapagliflozin (CHEBI:85078) is a diarylmethane (CHEBI:51614) |
| dapagliflozin (CHEBI:85078) is a monochlorobenzenes (CHEBI:83403) |
| dapagliflozin (CHEBI:85078) is a organic molecular entity (CHEBI:50860) |
| Incoming Relation(s) |
| dapagliflozin propanediol monohydrate (CHEBI:85079) has part dapagliflozin (CHEBI:85078) |
| IUPAC Name |
|---|
| (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol |
| INNs | Source |
|---|---|
| dapagliflozin | KEGG DRUG |
| dapagliflozina | WHO MedNet |
| dapagliflozine | WHO MedNet |
| Synonyms | Source |
|---|---|
| (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol | ChemIDplus |
| LYN-045 | ChEMBL |
| Brand Names | Source |
|---|---|
| BMS 512148 | ChemIDplus |
| BMS-512148 | ChemIDplus |
| Dapagliflozin component of br1019 | ChEMBL |
| Dapagliflozin component of qtern | ChEMBL |
| Dapagliflozin component of qternmet | ChEMBL |
| Dapagliflozin component of qternmet dapaglifozin | ChEMBL |
| Manual Xrefs | Databases |
|---|---|
| 4304 | DrugCentral |
| D08897 | KEGG DRUG |
| Dapagliflozin | Wikipedia |
| DB06292 | DrugBank |
| Registry Numbers | Sources |
|---|---|
| Reaxys:11966426 | Reaxys |
| CAS:461432-26-8 | KEGG DRUG |
| CAS:461432-26-8 | ChemIDplus |
| Citations |
|---|